Detalhe da pesquisa
1.
Combined SET7/9 and CDK4 inhibition act synergistically against osteosarcoma.
Biochem Biophys Res Commun
; 708: 149808, 2024 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38520914
2.
Predictive value of peripheral blood biomarkers in patients with non-small-cell lung cancer responding to anti-PD-1-based treatment.
Cancer Immunol Immunother
; 73(1): 12, 2024 Jan 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38231411
3.
In situ chemoimmunotherapy hydrogel elicits immunogenic cell death and evokes efficient antitumor immune response.
J Transl Med
; 22(1): 341, 2024 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38594751
4.
Targeting PCSK9 to upregulate MHC-II on the surface of tumor cells in tumor immunotherapy.
BMC Cancer
; 24(1): 445, 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38600469
5.
Design of a single-center, phase II trial to explore the efficacy and safety of 'R-ISV-RO' treatment in advanced tumors.
Future Oncol
; 2024 Mar 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38445361
6.
Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer.
Cancer Sci
; 114(7): 2798-2809, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37151176
7.
Prognostic value of genetic aberrations and tumor immune microenvironment in primary acral melanoma.
J Transl Med
; 21(1): 78, 2023 02 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36739402
8.
Enhanced systemic tumor suppression by in situ vaccine combining radiation and OX40 agonist with CpG therapy.
J Transl Med
; 21(1): 619, 2023 09 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37700338
9.
A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma.
Invest New Drugs
; 41(1): 162-167, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36763233
10.
Tumor-penetrating peptide internalizing RGD enhances radiotherapy efficacy through reducing tumor hypoxia.
Cancer Sci
; 113(4): 1417-1427, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35133063
11.
Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Efficacy, and Biomarkers.
Oncologist
; 2022 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35445725
12.
Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial.
Cancer Immunol Immunother
; 71(8): 1897-1908, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34984540
13.
Fatty Acid Metabolism and Cancer Immunotherapy.
Curr Oncol Rep
; 24(5): 659-670, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35230593
14.
Lymph node-targeted neoantigen nanovaccines potentiate anti-tumor immune responses of post-surgical melanoma.
J Nanobiotechnology
; 20(1): 190, 2022 Apr 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35418151
15.
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Lancet Oncol
; 22(7): 977-990, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34143971
16.
Deep Penetration of Nanolevel Drugs and Micrometer-Level T Cells Promoted by Nanomotors for Cancer Immunochemotherapy.
J Am Chem Soc
; 143(31): 12025-12037, 2021 08 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34320319
17.
Identification of a peptide binding to cancer antigen Kita-kyushu lung cancer antigen 1 from a phage-display library.
Cancer Sci
; 112(10): 4335-4345, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34387029
18.
Tumor eradicated by combination of imiquimod and OX40 agonist for in situ vaccination.
Cancer Sci
; 112(11): 4490-4500, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34537997
19.
FGFR2 alteration as a potential therapeutic target in poorly cohesive gastric carcinoma.
J Transl Med
; 19(1): 401, 2021 09 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34551773
20.
Lipophilic recombinant-protein insertion endows lymphocytes with enhanced targeting-infiltration ability in EGFR positive cancer.
Cell Immunol
; 365: 104376, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33984534